Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

306
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
306
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

58
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
58
Drug Regulation01:25

Drug Regulation

3.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.2K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.2K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.2K
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

330
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
330
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.6K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmaceutical Approval Update.

P & T : a peer-reviewed journal for formulary management·2019
Same author

Pharmaceutical Approval Update.

P & T : a peer-reviewed journal for formulary management·2019
Same author

Pharmaceutical Approval Update.

P & T : a peer-reviewed journal for formulary management·2019
Same author

Pharmaceutical Approval Update.

P & T : a peer-reviewed journal for formulary management·2019
Same author

Pharmaceutical Approval Update.

P & T : a peer-reviewed journal for formulary management·2019
Same author

Pharmaceutical Approval Update.

P & T : a peer-reviewed journal for formulary management·2018

Related Experiment Video

Updated: Mar 10, 2026

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

4.6K

Pharmaceutical Approval Update.

Michele B Kaufman

    P & T : a Peer-Reviewed Journal for Formulary Management
    |December 20, 2016
    PubMed
    Summary
    This summary is machine-generated.

    This summary covers three medications: Lisinopril oral solution for cardiovascular conditions, etanercept-szzs for autoimmune diseases, and lumacaftor/ivacaftor for cystic fibrosis treatment.

    More Related Videos

    Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
    06:34

    Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

    Published on: November 29, 2024

    665
    Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
    10:33

    Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

    Published on: December 17, 2021

    3.3K

    Related Experiment Videos

    Last Updated: Mar 10, 2026

    Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
    09:30

    Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

    Published on: March 17, 2023

    4.6K
    Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
    06:34

    Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

    Published on: November 29, 2024

    665
    Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
    10:33

    Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

    Published on: December 17, 2021

    3.3K

    Area of Science:

    • Pharmacology
    • Internal Medicine
    • Genetics

    Background:

    • Hypertension, heart failure, and acute myocardial infarction are significant cardiovascular diseases.
    • Autoimmune disorders represent a complex group of chronic conditions.
    • Cystic fibrosis is a genetic disorder affecting multiple organs.

    Purpose of the Study:

    • To review the therapeutic applications of Lisinopril oral solution (Qbrelis).
    • To discuss the use of etanercept-szzs (Erelzi) in managing autoimmune conditions.
    • To highlight the efficacy of lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.

    Main Methods:

    • Literature review of clinical trials and prescribing information.
    • Analysis of pharmacological data for each drug.
    • Synthesis of evidence regarding treatment outcomes.

    Main Results:

    • Lisinopril oral solution demonstrates efficacy in treating hypertension, heart failure, and acute myocardial infarction.
    • Etanercept-szzs is indicated for various autoimmune disorders, offering a treatment option.
    • Lumacaftor/ivacaftor provides a targeted therapy for cystic fibrosis patients.

    Conclusions:

    • These medications represent important advancements in managing cardiovascular diseases, autoimmune disorders, and cystic fibrosis.
    • The availability of these specific formulations and drug combinations expands therapeutic options for patients.
    • Further research may explore expanded indications and comparative effectiveness.